Comparative Pharmacology
Head-to-head clinical analysis: DOCOSANOL versus TPOXX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOCOSANOL versus TPOXX.
DOCOSANOL vs TPOXX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Docosanol is a saturated fatty alcohol that inhibits fusion between the host cell plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry and replication.
TPOXX (tecovirimat) inhibits the orthopoxvirus VP37 envelope protein, preventing viral egress from infected cells and reducing viral spread.
Apply a thin layer of 10% cream to affected area 5 times daily until healing is complete, typically 4-6 days.
600 mg orally twice daily for 14 days.
None Documented
None Documented
Due to negligible systemic absorption, a terminal elimination half-life is not defined for topical docosanol. In vitro studies of hepatic metabolism suggest a plasma half-life of approximately 1 hour if systemically absorbed, but clinical relevance is absent.
Terminal half-life ~19 hours (range 10–48 h) in healthy adults; prolonged in renal impairment (up to ~100 h).
Docosanol is a topical agent with negligible systemic absorption; no significant renal or fecal elimination occurs after topical application. In animal studies, less than 1% of a topical dose was excreted in urine or feces as unchanged drug or metabolites.
Fecal (primarily as unchanged drug, ~75%); renal (~25%, mostly as metabolites; <2% unchanged in urine).
Category C
Category C
Antiviral Agent
Antiviral Agent